Expensive but exceptional! 2 FTSE 100 stocks I’d buy following latest news

These FTSE 100 (INDEXFTSE: UKX) shares might not be the cheapest. But if you’re looking to make big returns, Royston Wild reckons they’re worth a serious look.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN) is now in great shape to put the profits turbulence of the past decade well and truly behind it. How so? Well, there’s been huge efforts undertaken to supercharge its product pipeline and put the problems of patent expirations of critical revenues-driving drugs to bed.

Less than a decade ago, the FTSE 100 pharma giant appeared in dire straits as its lab teams lagged those of the competition by a county mile. Under chief executive Pascal Soriot, however, and the strides he has made to modernise AstraZeneca’s R&D culture, its success in getting new products from testing stage to pharmacy shelf has improved considerably.

This was apparent in first-quarter results released last week in which the sales rate of new medicines was again very impressive, up 83% from the same 2018 period. What’s more, promising news concerning its drugs pipeline in the quarter, like the regulatory approval of metastatic breast cancer treatment Lynparza and diabetes-battler Farxiga in the European Union, underlines my belief there’ll be much more to come.

City analysts believe so too, and are predicting that a 1% predicted earnings improvement at AstraZeneca will jump to 22% next year. A forward P/E ratio of 21.5 times may make the business expensive on paper, but I reckon the rate at which its new medicines are hitting the market and are being snapped up by consumers all over the globe, still makes the firm a white-hot buy despite this premium.

It’s not just a sales story

Associated British Foods (LSE: ABF) is a blue-chip I’ve long lauded over the exceptional growth potential of its critical Primark budget fashion business.

I was delighted, then, to see operating profits here continued to blast higher in the 24 weeks to March 2, up 25% year-on-year to £426m. Conditions remain tough for retailers but sales are still growing at Primark. Thak’s thanks to market share grabs driven by great product lines and the attractiveness of its prices in tough times for consumers in many parts of Europe and not just the UK.

Now ABF is exploiting this to the max by aggressively expanding its retail space, which rose by 800,000 sq ft year-on-year to 15.1m sq ft as of the beginning of March. A surging top line, however, is only part of the story. The Footsie company is also bolstering margins through a combination of reduced discounting, better stock management, and improved buying. Such endeavours helped operating margin in the half-year period gallop to 11.7% from 9.8% in the previous year.

Forecasters from the Square Mile believe Primark has much more to give as well. It’s why they reckon earnings growth at ABF will jump from 1% in the fiscal year to September 2019 to 11% the following year. So I say forget about the firm’s high prospective P/E multiple of 18.9 times and buy in as the retailer’s quest for speedy international growth could deliver some stunning shareholder returns in the years ahead.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has recommended Associated British Foods and AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »